In a clinical trial that included 48 patients led by the Johns Hopkins Bloomberg School of Public Health, a single-dose vaccine against dengue—the most prevalent mosquito-borne virus in the world—provided complete protection for all 21 participants who received it (Kirkpatrick BD et al. Sci Transl Med. 2016;8:330ra36).
The TV003 vaccine, developed by scientists at the National Institute of Allergy and Infectious Diseases, contains live, attenuated viral particles of the 4 different dengue serotypes that can cause high fever; severe headaches; severe pain behind the eyes; rash; and joint, muscle, or bone pain. Researchers have demonstrated TV003’s effectiveness against dengue 1, 3, and 4—but not dengue 2, for which there is no known effective vaccine. Importantly, previous infection with dengue is the greatest risk factor for more severe disease when subsequently infected with a different dengue serotype.
Hampton T. Dengue Vaccine Performs Well in Small Clinical Trial. JAMA. 2016;315(17):1825. doi:10.1001/jama.2016.4339